

IN THE CLAIMS:

Please cancel claim 2.

Please amend claims 1 and 3-10, without prejudice, as follows:

1. (Currently Amended) A pharmaceutical kit comprising:

- (i) a solubilized or unsolubilized ~~aryl-heterocyclic compound~~ ziprasidone; and
- (ii) a liquid vehicle comprising a viscosity agent, with the proviso that when said ~~aryl-heterocyclic compound~~ ziprasidone is unsolubilized, said liquid vehicle further contains a solubilizer.

2. (Canceled)

3. (Currently Amended) The pharmaceutical kit of Claim 2 1 wherein said solubilizer is a cyclodextrin.

4. (Currently Amended) The pharmaceutical kit of Claim 3 2 wherein said cyclodextrin is γ -cyclodextrin, β -cyclodextrin, HPBCD, SBECD, or a mixture thereof.

5. (Currently Amended) The pharmaceutical kit of Claim 2 1 wherein said viscosity agent comprises a cellulose derivative, polyvinylpyrrolidone, alginates, chitosan, a dextran, gelatin, polyethylene glycols, polyoxyethylene ethers, polyoxypropylene ethers, polylactides, polyglycolides, polycaprolactones, polyanhydrides, polyamines, polyurethanes, polyesteramides, polyorthoesters, polydioxanones, polyacetals, polycarbonates, polyorthocarbonates, polyphosphazenes, succinates, polycarbonates, poly(maleic acid), poly(amino acids), polyhydroxycellulose, chitin, copolymers or terpolymers of the foregoing, sucrose acetate isobutyrate, PLGA, stearic acid/NMP, or a combination thereof.

6. (Currently Amended) The pharmaceutical kit of Claim 3 1 wherein said viscosity agent comprises a cellulose derivative, polyvinylpyrrolidone, alginates, chitosan, a dextran, gelatin, polyethylene glycols, polyoxyethylene ethers, polyoxypropylene ethers, polylactides, polyglycolides, polycaprolactones, polyanhydrides, polyamines, polyurethanes, polyesteramides, polyorthoesters, polydioxanones, polyacetals, polycarbonates, polyorthocarbonates, polyphosphazenes, succinates, polycarbonates, poly(maleic acid), poly(amino acids), polyhydroxycellulose, chitin, copolymers or terpolymers of the foregoing, sucrose acetate isobutyrate, PLGA, stearic acid/NMP, or a combination thereof.

7. (Currently Amended) The pharmaceutical kit of Claim 5 4 wherein said cellulose derivatives include methyl cellulose, sodium carboxymethyl cellulose or hydroxypropyl methyl cellulose; and wherein said polylactides, polyglycolides, or copolymers and terpolymers thereof include poly-lactic-co-glycolic acid.

8. (Currently Amended) The pharmaceutical kit of Claim 2 1 wherein said liquid vehicle (ii) further contains a pharmaceutically acceptable surfactant.

9. (Currently Amended) The pharmaceutical kit of Claim 3 2 wherein said liquid vehicle (ii) further contains a pharmaceutically acceptable surfactant.

10. (Currently Amended) The pharmaceutical kit of Claim 8 7 wherein said surfactant is a polyoxyethylene sorbitan ester.

11. (Original) A pharmaceutical kit for an injectable depot formulation comprising:

- (i) a first package containing ziprasidone; and
- (ii) a second package containing an aqueous solution of a cyclodextrin, a cellulose-derived viscosity agent, and optionally a pharmaceutically acceptable surfactant.

12. (Original) The pharmaceutical kit for an injectable depot formulation of Claim 11 wherein said ziprasidone is present in an amount sufficient to provide at least about 0.5 to about 350 mg ziprasidone per ml; said cyclodextrin is present in an amount sufficient to form a concentration of up to about 60% w/v; said cellulose-derived viscosity agent is present in a concentration of from about 0.5 to about 3% w/v; and said surfactant is optionally present in an amount sufficient to form a concentration of up to about 1% w/v.

13. (Original) The pharmaceutical kit for an injectable depot formulation of Claim 11 wherein said ziprasidone is present in an amount sufficient to provide at least about 10 mgA to about 210 mgA ziprasidone per ml of said depot formulation.

14. (Original) The pharmaceutical kit of Claim 11 wherein said ziprasidone is ziprasidone mesylate; said cyclodextrin is SBECD; said cellulose-derived viscosity agent is NaCMC; and said optional surfactant is a polyoxyethylene sorbitan ester.

15. (Original) A pharmaceutical kit for preparing an intramuscular depot injection formulation of ziprasidone comprising:

- (i) a first package containing sterilized, micronized ziprasidone mesylate; and
- (ii) a second package containing a solution of: water suitable for injection; SBECD in an amount sufficient to form a concentration of about 5% to about 35% w/v of said depot injection formulation; NaCMC in an amount sufficient to form a concentration of about 0.1% to about 3% w/v of said depot injection formulation; and a polyoxyethylene sorbitan ester in an amount sufficient to form a concentration of up to about 1% w/v of said depot injection formulation;

wherein said solution of (ii) is present in an amount sufficient to provide an injection volume of about 1 to about 3 ml injection, and said ziprasidone of (i) is present in an amount effective to deliver about 10 to about 30 mg per day of ziprasidone for about 1 to about 2 weeks in said injection volume.

16. (Original) A method of preparing an injectable depot formulation comprising: contacting a solubilized or unsolubilized substantially dry aryl-heterocyclic compound with an aqueous liquid containing a viscosity agent and optionally a pharmaceutically acceptable surfactant to form a suspension, with the provisos that when said aryl-heterocyclic compound is unsolubilized: a) said aqueous liquid further contains a solubilizer, and b) said contacting is for a period of time sufficient to effect solubilization of said aryl-heterocyclic compound with said solubilizer prior to injecting said depot formulation.

17. (Original) The method of Claim 16 wherein said aryl-heterocyclic compound is unsolubilized ziprasidone; said solubilizer is a cyclodextrin; and said viscosity agent is a cellulose derivative.